A Chart Review to Evaluate the Safety and Efficacy of MeRT on Subjects With ASD

Wave Neuroscience141 enrolled

Overview

The purpose of this study is to evaluate the safety and efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) on subjects with Autism Spectrum Disorder (ASD).

This is a retrospective chart review of 200 consecutive charts of subjects ages 2-20 years old seen at the Brain Treatment Center between 2010 and 2015. The review is designed to evaluate the safety and efficacy of Magnetic Electroencephalogram/Electrocardiogram(EEG/ECG)-Guided Resonance Therapy (MeRT) on subjects with Autism Spectrum Disorder (ASD).

Study Type

OBSERVATIONAL

Enrollment

141

Conditions

Autistic Disorder

Interventions

MeRT Efficacy Chart ReviewOTHER

There will be not intervention. This is a chart review.

Eligibility

Sex: ALLMin age: 2 YearsMax age: 20 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Must have completed a baseline EEG at the Brain Treatment Center (BTC) 2. Age between 2 and 20 years old at initial visit 3. Must have a diagnosis of ASD according to the prevailing standard at that time (i.e., Diagnostic and Statistical Manual-IV (DSM-IV)) (ASD Group only) 4. Must have received Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) for more than (5) sessions (ASD Group only) Exclusion Criteria: 5. Clinically significant abnormality or clinically significant unstable medical condition during treatment that in the Investigator's judgment may have may limited interpretation of the results.

Locations (1)

Brain Treatment Center

Newport Beach, California, United States

Outcomes

Primary Outcomes

Childhood Autism Rating Scale (CARS)

Symptom reduction in ASD will be measured using the reduction in the CARS between two time points: Baseline (BL) CARS and Final CARS Evaluation.

Time frame: Baseline through study completion, an average of 36 months

Secondary Outcomes

Electrophysiological

Changes in quantitative electroencephalogram (qEEG), will be measured with emphasis on the overall changes between two timepoints: BL EEG and Final EEG.

Time frame: Baseline through study completion, an average of 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.